Skip to main content

ANVS

Stock
Health Care
Biotechnology

Performance overview

ANVS Price
Price Chart

Forward-looking statistics

Beta
1.41
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.

Company info

SectorHealth Care
IndustryBiotechnology
Employees7
Market cap$68.9M

Fundamentals

Enterprise value$20.0M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity0.00

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)-$2.24
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$1M
Avg trading volume (10 day)$1M
Put-call ratio

Macro factor sensitivity

Growth-5.9
Credit+10.3
Liquidity+0.7
Inflation-8.1
Commodities-2.9
Interest Rates+0.2

Valuation

Dividend yield0.00%
PEG Ratio-1.30
Price to sales
P/E Ratio-1.30
Enterprise Value to Revenue
Price to book1.91

Upcoming events

Next earnings dayMay 14, 2025
Next dividend day
Ex. dividend day

News

All You Need to Know About Annovis Bio (ANVS) Rating Upgrade to Buy

Annovis Bio (ANVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research (June 11, 2025)
FDA Gives Green Signal To Annovis Bio's Parkinson's Trial With Buntanetap

Annovis Bio Inc (NYSE: ANVS) received notice from the FDA that the Phase 3 clinical study with buntanetap in early Parkinson's patients may proceed.  The FDA accepted the final protocol and the clinical development plan and approved using the company's new large-scale.

Benzinga (July 7, 2022)
Annovis CEO on its Alzheimer's drug: 'We may have something that gives hope to people'

Maria Maccecchini, Annovis CEO, joins Yahoo Finance's Alexis Christoforous and Kristin Myers to discuss the company's positive Alzheimer's drug study.

Yahoo Finance (May 30, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free